Skip to main content
. Author manuscript; available in PMC: 2017 Sep 2.
Published in final edited form as: Circ Res. 2016 Jul 18;119(6):e91–e103. doi: 10.1161/CIRCRESAHA.116.308955

Figure 5. LNK loss of function and cholesterol enrichment increase platelet AKT activation. (a).

Figure 5

TPO/Mpl signaling in resting platelets of WT and Lnk −/− BM recipient mice without TPO treatment. (b) AKT activity in platelets from WT and Lnk −/− BM recipient mice with and without platelet agonist AYPGKF stimulation. (c) effect of ex ex vivo cholesterol loading on AKT activity from platelets of chow fed mice. (d) effect of Jak2 and AKT inhibitors on platelets of WT and Lnk −/− BM recipient mice (n=4). (e) p-SHIP1 level in platelets of WT and Lnk −/− BM recipient mice with and without AYPGKF stimulation. (f) change of AKT activity after HDL and Lyn tyrosine kinase activator Tolimidone treatment in Lnk−/− platelets from WTD fed mice. (g) p-SHIP1 levels in WT and Lynkd/kd platelets upon AYPGKF stimulation. (h) platelet activity of Lynkd/kd mice upon AYPGKF stimulation. (i) cholesterol loading effect on platelet activity of Lynkd/kd mice.